Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Humanized anti-CD117 Monoclonal Antibody (JSP191)
Humanized anti-CD117 Monoclonal Antibody · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Blood Stem Cell Transplant w/ anti-CD117 conditioning | EXPERIMENTAL | The phase 1a portion of the study plans to assess approximately 3 planned dose cohorts of JSP191: 0.3 mg/kg, 0.6 mg/kg, and 1.0 mg/kg to determine the maximum tolerated dose for expansion. Subjects will receive a single dose of intravenous JSP191 antibody followed by monitoring for antibody clearance. Once the antibody has cleared below a certain level, patients will receive stem cell transplant and be monitored for hematopoietic recovery. The phase 1b portion of the study will enroll additional subjects at the expansion dose in order to further explore the safety, feasibility, and PK of that dose. |
| Name | Type | Description |
|---|---|---|
| Humanized anti-CD117 Monoclonal Antibody (JSP191) | BIOLOGICAL | Procedure: single intravenous infusion of JSP191 antibody |
Key Inclusion Criteria: * AML/MDS as defined by specific criteria, including but not limited to the following subtypes: 1. AML in CR 2. MDS \< 5% BM blasts 3. MDS 5 - 10% BM blasts 4. AML not in CR or MDS \> 10% BM blasts * Patients with human leukocyte antigen (HLA) matched related or unr...
Top 20 of 31 competitors
JSP191 is an investigational monoclonal antibody being studied as a conditioning regimen for patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) who are undergoing allogeneic hematopoietic stem cell transplantation. It is designed to be given before transplant to prepare patients for donor stem cell engraftment.
JSP191 targets CD117, also known as KIT, a receptor found on hematopoietic stem cells. By binding CD117, the humanized antibody is intended to deplete host stem cells and create space in the bone marrow for donor cells, a process called conditioning, prior to allogeneic stem cell transplantation.
JSP191 is being developed by Jasper Therapeutics, Inc., which trades on the Nasdaq under the ticker JSPR. The company is advancing the humanized anti-CD117 monoclonal antibody as a targeted conditioning agent for patients with myelodysplastic syndrome and acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation.
JSP191 is in Phase 1 clinical development. It is an investigational agent and has not been approved by the FDA. The completed Phase 1 trial evaluated the antibody as a conditioning regimen in patients with MDS and AML undergoing allogeneic hematopoietic stem cell transplantation.
JSP191 has been studied in the Phase 1 trial NCT04429191, titled JSP191 Antibody Conditioning Regimen in MDS/AML Subjects Undergoing Allogenic Hematopoietic Stem Cell Transplantation. The trial enrolled 32 participants in the United States, included adults 18 years and older, and has been completed.
Yes, JSP191 is the same asset as the humanized anti-CD117 monoclonal antibody. JSP191 is the development code name used by Jasper Therapeutics for this humanized monoclonal antibody targeting CD117, so searches for either name refer to the same investigational conditioning agent.